尼伏鲁单抗治疗转移性肾细胞癌：土耳其肿瘤学会肾癌数据库研究结果。
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
机构信息
Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, 06590, Turkey.
Cancer Research Institute, Ankara University, Ankara, 06590, Turkey.
出版信息
Future Oncol. 2021 Dec;17(35):4861-4869. doi: 10.2217/fon-2021-0717. Epub 2021 Nov 2.
The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes patients with mRCC from 13 cancer centers in Turkey. Patients with mRCC treated with nivolumab in the second line and beyond were extracted from the TKCC database. A total of 173 patients were included. The rates of patients treated with nivolumab in the second, third, fourth and fifth lines were 47.4%, 32.4%, 14.5% and 5.7%, respectively. The median overall survival and progression-free survival were 24.2 months and 9.6 months, respectively. Nivolumab was discontinued owing to adverse events in 11 (6.4%) patients. Nivolumab was effective in patients with mRCC and no new safety signal was observed.
作者报告了纳武利尤单抗治疗转移性肾细胞癌（mRCC）患者的疗效和安全性的真实世界数据。土耳其肿瘤学会肾癌协作组（TKCC）数据库纳入了来自土耳其 13 家癌症中心的 mRCC 患者。从 TKCC 数据库中提取了接受纳武利尤单抗二线及以上治疗的 mRCC 患者。共纳入 173 例患者。接受纳武利尤单抗二线、三线、四线和五线治疗的患者比例分别为 47.4%、32.4%、14.5%和 5.7%。中位总生存期和无进展生存期分别为 24.2 个月和 9.6 个月。由于不良事件，11 例（6.4%）患者停止使用纳武利尤单抗。纳武利尤单抗对 mRCC 患者有效，且未观察到新的安全性信号。
Zotero 插件